Indivior PLC

Report Publication Announcement • Oct 10, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1244T

Indivior PLC

10 October 2017

Indivior to Announce 2017 Third Quarter and Year-to-Date Results on November 2nd

Slough, UK, and Richmond, VA, 10 October 2017 - Indivior PLC (LON: INDV) today announced that it will release its 2017 third quarter and year-to-date results on November 2nd at 11:00 a.m. London time (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.

Key members of Indivior's leadership team led by Shaun Thaxter, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12 noon London time (8:00 a.m. U.S. Eastern) on November 2nd.

Access the Live Webcast for the Results Call on November 2nd

The webcast event will be available on the "Investors" section of the company's website at www.indivior.com. The webcast link is https://edge.media-server.com/m6/p/b6jz7h6i. Participants also may access the results presentation telephonically: US participants 1-646-254-3361; international participants 44(0)20-3427-1901. Please reference confirmation number 9592820. A replay of the presentation will be available at www.indivior.com.

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: 804-423-8916 or jason.thompson@indivior.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOREAXENEEAXFFF